Iovance Biotherapeutics (IOVA) Price & Analysis

Compare

3,737 Followers

IOVA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.64 - $12.51

Previous CloseN/A

Volume2.95M

Average Volume (3M)21.18M

Market Cap

$806.93M

Enterprise Value$327.34M

Total Cash (Recent Filing)$301.18M

Total Debt (Recent Filing)$53.17M

Price to Earnings (P/E)―

Beta2.15

Next Earnings

Nov 06, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding361,853,880

10 Day Avg. Volume12,568,281

30 Day Avg. Volume21,177,515

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.41

Enterprise Value/Revenue1.36

Enterprise Value/Gross Profit6.58

Enterprise Value/Ebitda-0.91

Forecast

1Y Price Target

$10.67

Price Target Upside382.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Regulatory ApprovalAMTAGVI approved in Canada for advanced melanoma, marking the first T cell therapy for a solid tumor in the country.

Revenue GrowthThe total 2Q25 product revenue of $60 million is in line with estimates and represents a 93% increase compared to the same period in 2024.

Strategic RestructuringIovance is entering a strategic restructuring estimated to save approximately $100 million annually, reduce cash burn, and improve gross margins without significant changes to the clinical pipeline.

Bears Say

Regulatory ChallengesIOVA withdrew its application to the EMA following lack of alignment during discussions on clinical data.

Revenue MissThe stock reacted negatively after-hours to 2Q results due to a revenue miss mainly from IL-2.

Stock PerformanceThe stock was down approximately 35% in after-hours trading due to lackluster revenue and a lack of concrete catalysts or milestones in the near term.

Iovance Biotherapeutics News

Iovance Biotherapeutics reports inducement grants under NASDAQ listing rule

Iovance Biotherapeutics (IOVA) announced that on August 21, 2025, the Company approved the grant of inducement stock options...

11d ago

IOVA

Home Depot reports Q2 results, SoftBank invests $2B in Intel: Morning Buzz

The major averages were mixed near noon as traders await signals from the upcoming Jackson Hole symposium and...

16d ago

Iovance Amtagvi receives Health Canada approval for advanced melanoma

Iovance Biotherapeutics (IOVA) announced Health Canada has issued a notice of compliance with conditions for Amtagvi, a tumor-derived...

17d ago

IOVA

Tesla disbands supercomputer team, Trade Desk Q2 spurs downgrades: Morning Buzz

The major averages were broadly higher near noon amid growing expectations that the Federal Reserve may move toward...

27d ago

Iovance Biotherapeutics price target lowered to $14 from $18 at Wells Fargo

Wells Fargo lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $14 from $18 and keeps an...

27d ago

IOVA

Iovance Biotherapeutics reports Q2 EPS (33c), consensus 928c)

Reports Q2 revenue $59.95M, consensus $67.14M. Frederick Vogt, Interim President and Chief Executive Officer of Iovance, stated, “In...

28d ago

IOVA

Iovance Biotherapeutics backs FY25 revenue view $250M-$200M, consensus $287.11M

The company said, “Iovance is reiterating total product revenue guidance within the range of $250 to $300 million...

28d ago

IOVA

Iovance Biotherapeutics options imply 23.8% move in share price post-earnings

Pre-earnings options volume in Iovance Biotherapeutics (IOVA) is 1.2x normal with calls leading puts 4:3. Implied volatility suggests...

28d ago

IOVA

Iovance Biotherapeutics Updates Corporate Presentation

An update from Iovance Biotherapeutics ( ($IOVA) ) is now available. On August 29, 2025, Iovance Biotherapeutics updated...

6d ago

IOVA

Iovance Biotherapeutics Amends Sale Agreement with Jefferies

The latest update is out from Iovance Biotherapeutics ( ($IOVA) ). On August 22, 2025, Iovance Biotherapeutics entered...

13d ago

IOVA

Iovance Biotherapeutics Gains Health Canada Approval

Iovance Biotherapeutics ( ($IOVA) ) has shared an update. On August 18, 2025, Iovance Biotherapeutics announced that its...

16d ago

IOVA

Iovance Biotherapeutics’ Canadian Approval of AMTAGVI: A Milestone in T Cell Therapy and Stock Growth Potential

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics and keeping the price target...

16d ago

IOVA

Iovance Biotherapeutics’ Earnings Call Highlights Growth

Iovance Biotherapeutics (($IOVA)) has held its Q2 earnings call. Read on for the main highlights of the call....

23d ago

IOVA

Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025

Iovance Biotherapeutics ( ($IOVA) ) has released its Q2 earnings. Here is a breakdown of the information Iovance...

28d ago

IOVA

IOVA FAQ

What was Iovance Biotherapeutics Inc’s price range in the past 12 months?

Iovance Biotherapeutics Inc lowest stock price was $1.64 and its highest was $12.51 in the past 12 months.

What is Iovance Biotherapeutics Inc’s market cap?

Iovance Biotherapeutics Inc’s market cap is $806.93M.

When is Iovance Biotherapeutics Inc’s upcoming earnings report date?

Iovance Biotherapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 63 days.

How were Iovance Biotherapeutics Inc’s earnings last quarter?

Iovance Biotherapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.047.

Is Iovance Biotherapeutics Inc overvalued?

According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Iovance Biotherapeutics Inc pay dividends?

Iovance Biotherapeutics Inc does not currently pay dividends.

What is Iovance Biotherapeutics Inc’s EPS estimate?

Iovance Biotherapeutics Inc’s EPS estimate is -0.25.

How many shares outstanding does Iovance Biotherapeutics Inc have?

Iovance Biotherapeutics Inc has 361,853,880 shares outstanding.

What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?

Iovance Biotherapeutics Inc reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went down -20.076%.

Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?

Currently, no hedge funds are holding shares in IOVA

Iovance Biotherapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-53.16%

Trailing 12-Months

Asset Growth

-5.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Iovance Biotherapeutics Inc

Iovance Biotherapeutics (IOVA) is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment. The company specializes in tumor-infiltrating lymphocyte (TIL) therapy, an approach that harnesses the body's immune system to target and destroy cancer cells. Iovance is primarily engaged in the research, development, and commercialization of its lead product candidate, Lifileucel, which is designed for the treatment of metastatic melanoma and other solid tumors. The company operates in the biopharmaceutical sector, aiming to provide effective therapeutic options to patients with challenging cancers.

Iovance Biotherapeutics (IOVA) Earnings & Revenues

Historic Earnings Reports

IOVA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong positive outlook with significant revenue growth, successful adoption of Amtagvi, and strategic restructuring to improve profitability. Despite increased expenses and a setback in European regulatory strategy, the overall momentum and achievements outweigh the challenges.View all IOVA earnings summaries

IOVA Stock 12 Month Forecast

Average Price Target

$10.67

▲(382.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,4.012307692307693,5.344615384615385,6.676923076923078,8.00923076923077,9.341538461538462,10.673846153846155,12.006153846153847,13.338461538461539,14.670769230769231,16.003076923076925,17.335384615384616,18.66769230769231,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,3.2946153846153847,3.9092307692307697,4.523846153846154,5.138461538461539,5.753076923076923,6.367692307692309,6.9823076923076925,7.596923076923078,8.211538461538462,8.826153846153847,9.44076923076923,10.055384615384616,{"y":10.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,2.550769230769231,2.4215384615384616,2.2923076923076926,2.163076923076923,2.033846153846154,1.9046153846153848,1.7753846153846156,1.6461538461538463,1.516923076923077,1.3876923076923078,1.2584615384615385,1.1292307692307695,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >